Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Pfizer's COVID drug data supports use in high-risk patients - FDA staff (March 14)

Published 03/14/2023, 09:29 AM
Updated 03/15/2023, 06:31 AM
© Reuters.

© Reuters.

(This March 14 story has been corrected to show that Dryden-Peterson is "director of outpatient COVID treatments at Mass General Brigham", and not of the hospital in paragraph 8)

By Khushi Mandowara and Leroy Leo

(Reuters) - The U.S. health regulator's staff reviewers said on Tuesday data from Pfizer Inc (NYSE:PFE)'s COVID-19 drug trials support its use in adults at high risk of progressing to severe disease, bringing the pill closer to a full approval.

The Food and Drug Administration made its assessment in briefing documents ahead of a meeting of the agency's external advisers on Thursday to discuss full approval to use Pfizer's oral pill for high-risk COVID-19 patients exhibiting mild to moderate symptoms.

The FDA's advisers will vote on whether the benefits related to Paxlovid outweigh its risks. The agency typically follows the advice of its expert advisers, but is not mandated to do so.

Paxlovid has been authorized for emergency use since late 2021, and a full approval is likely to allow Pfizer to expand its advertising campaign for the drug.

Over 12 million courses have been delivered to pharmacies, and patients have used over 8 million courses of the treatment, according to Federal data.

There have been multiple reports on COVID rebounds in some people after taking Paxlovid, including President Joe Biden and Dr Anthony Fauci, the then director of National Institute of Allergy and Infectious Diseases, last year.

However, during mid-to-late stage trials of the drug, overall rates of symptom rebound ranged from 10% to 16%, with no evidence of a higher rebound rate in patients who received the drug or the placebo, regardless of their risk to severe disease, or whether Omicron or an earlier variant was dominant, the reviewers said.

© Reuters. FILE PHOTO: Paxlovid, Pfizer's anti-viral medication to treat the coronavirus disease (COVID-19), is displayed in this picture illustration taken October 7, 2022. A morning and an evening does consists of one white 100-milligram tablet of Ritonavir and two pink 150-milligram tablets of PF-07321332. REUTERS/Wolfgang Rattay/Illustration

Dr Scott Dryden-Peterson, director of outpatient COVID treatments at Mass General Brigham in Boston, said the data was the best evidence against COVID rebound, fears of which were limiting uptake, and the full approval would allow doctors flexibility in prescribing the drug.

Paxlovid has shown reduction in risk of hospitalization or death by 86% in non-hospitalized, high-risk adult patients in Pfizer' study, which did not include vaccinated participants.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.